FDA lifts clinical hold on BioSante prostate cancer vaccine

The FDA’s clinical hold on BioSante Pharmaceuticals’ (NASDAQ:BPAX) GVAX prostate cancer vaccine for the treatment of prostate cancer has been lifted by FDA. BioSante said manufacturing of new vaccine is complete, and planning for a Phase 2 clinical trial at the Johns Hopkins Kimmel Cancer Center is underway. BioSante funded the manufacturing of the vaccine and [...]

OncoVista gives personalized medicine a twist

Taking personalized medicine to the next level, Alexander Weis likes to say that OncoVista Innovative Therapies (OTCBB:OVIT) is using a “targeted” approach to preselect and treat cancer patients with drugs that are more effective and less toxic and that can improve their quality of life. “I don’t believe in one-size-fits-all treatments when usually only about [...]

OncoGenex prices $50 million offering

OncoGenex Pharmaceuticals (NASDAQ: OGXI) has priced a public offering of 3,174,602 units at $15.75 (U.S.) per unit, with each unit consisting of one common share and one-half of a warrant. The stock closed at 18.75 on Monday. Net proceeds of about $46.7 million will be used primarily to advance the company’s product pipeline, including its [...]

OncoGenex results in peer-reviewed journal

Phase 2 results of OncoGenex Pharmaceuticals’ (NASDAQ:OGXI) curtirsen drug, showing a survival benefit in patients with advanced prostate cancer, have been published in the Journal of Clinical Oncology. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone chemotherapy was 23.8 months, compared with 16.9 months for patients treated with docetaxel/prednisone [...]

DiagnoCure partner files prostate test with FDA

DiagnoCure’s (TSX:CUR) corporate partner has filed a premarket approvalapplication with the FDA for the Progensa PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer. DiagnoCure holds the worldwide rights to the PCA3 biomarker and in 2003, it granted an exclusive sub-license to [...]

Medical Lab division to drive Warnex

After obtaining rights to a colorectal cancer blood screening test in May, Warnex (TSX:WNX) is looking for additional products to license into its Medical Laboratories division as it seeks to become the “unique provider” of specialized diagnostic tests in Canada. “Our other divisions are coming out of the recession okay, and we getting busy.  But [...]

DiagnoCure’s PCA3 gets boost from GSK study

Two major studies presented last week at the Genitourinary symposium of the American Society of Clinical Oncology in San Francisco featured DiagnoCure’s PCA3 molecular test on subsets of patients in GlaxoSmithKline’s REDUCE trial of its prostate cancer drug dutasteride. “This four-year, multicentre, worldwide study is the largest to date performed on DiagnoCure’s PCA3 marker,” DiagnoCure (TSX:CUR) [...]